• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT.

作者信息

Gurnari Carmelo, Koster Linda, Baaij Laurien, Heiblig Mael, Yakoub-Agha Ibrahim, Collin Matthew, Passweg Jakob, Bulabois Claude E, Khan Anjum, Loschi Michael, Carnevale-Schianca Fabrizio, Crisà Elena, Caravelli Daniela, Kuball Jürgen, Saraceni Francesco, Olivieri Attilio, Rambaldi Alessandro, Kulasekararaj Austin G, Hayden Patrick J, Badoglio Manuela, Onida Francesco, Scheid Christof, Franceschini Franco, Mekinian Arsène, Savic Sinisa, Voso Maria Teresa, Drozd-Sokolowska Joanna, Snowden John A, Raj Kavita, Alexander Tobias, Robin Marie, Greco Raffaella, McLornan Donal P

机构信息

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

Translational Hematology and Oncology Research Department, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

出版信息

Blood Adv. 2024 Mar 26;8(6):1444-1448. doi: 10.1182/bloodadvances.2023012478.

DOI:10.1182/bloodadvances.2023012478
PMID:38330178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10955646/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27e0/10955646/8b3c360cf383/BLOODA_ADV-2023-012478-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27e0/10955646/8b3c360cf383/BLOODA_ADV-2023-012478-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/27e0/10955646/8b3c360cf383/BLOODA_ADV-2023-012478-gr1.jpg

相似文献

1
Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT.异基因造血细胞移植治疗VEXAS综合征：欧洲血液与骨髓移植协会多中心研究结果
Blood Adv. 2024 Mar 26;8(6):1444-1448. doi: 10.1182/bloodadvances.2023012478.
2
Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis.评估异基因造血细胞移植在 VEXAS 综合征中的疗效：系统评价和荟萃分析的结果。
Bone Marrow Transplant. 2024 Oct;59(10):1423-1427. doi: 10.1038/s41409-024-02375-3. Epub 2024 Jul 26.
3
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.异基因造血细胞移植在 VEXAS 综合征中的作用。
Ann Hematol. 2024 Nov;103(11):4427-4436. doi: 10.1007/s00277-024-05942-2. Epub 2024 Aug 22.
4
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.异基因造血干细胞移植治疗骨髓增生异常综合征中的种系易感性特征：一项基于调查的研究及欧洲血液与骨髓移植学会慢性恶性肿瘤工作组的立场文件
Lancet Haematol. 2023 Dec;10(12):e994-e1005. doi: 10.1016/S2352-3026(23)00265-X. Epub 2023 Oct 25.
5
Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older.异基因造血细胞移植对70岁及以上骨髓增生异常综合征患者是一种安全有效的治疗方法。
Biol Blood Marrow Transplant. 2017 Jan;23(1):1-2. doi: 10.1016/j.bbmt.2016.11.013. Epub 2016 Nov 16.
6
Which lower risk myelodysplastic syndromes should be treated with allogeneic hematopoietic stem cell transplantation?哪些低危骨髓增生异常综合征应采用异基因造血干细胞移植治疗？
Leukemia. 2020 Oct;34(10):2552-2560. doi: 10.1038/s41375-020-0967-x. Epub 2020 Jul 13.
7
[Two cases of VEXAS syndrome].[两例VEXAS综合征]
Lakartidningen. 2022 Sep 7;119:22024.
8
Allogeneic Stem Cell Transplantation for Patients Age ≥ 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT.年龄≥70岁的骨髓增生异常综合征患者的异基因干细胞移植：欧洲血液与骨髓移植协会慢性恶性肿瘤工作组骨髓增生异常综合征小组委员会的一项回顾性研究
Biol Blood Marrow Transplant. 2017 Jan;23(1):44-52. doi: 10.1016/j.bbmt.2016.09.027. Epub 2016 Oct 5.
9
Could it be VEXAS?这会是 VEXAS 吗？
Ann Hematol. 2024 Jun;103(6):2169-2171. doi: 10.1007/s00277-024-05750-8. Epub 2024 Apr 9.
10
Allogeneic stem cell transplantation as a curative therapeutic approach for VEXAS syndrome: a case report.异基因干细胞移植作为VEXAS综合征的一种治愈性治疗方法：一例病例报告。
Bone Marrow Transplant. 2022 Feb;57(2):315-318. doi: 10.1038/s41409-021-01544-y. Epub 2022 Jan 9.

引用本文的文献

1
Prevalence and outcome of VEXAS syndrome in unrelated hematopoietic cell transplantation for bone marrow failure.骨髓衰竭非亲缘造血细胞移植中VEXAS综合征的患病率及结局
Clin Exp Med. 2025 Aug 22;25(1):300. doi: 10.1007/s10238-025-01832-7.
2
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.用于治疗风湿性疾病的自体造血干细胞移植：欧洲血液与骨髓移植协会实践协调与指南委员会的最佳实践建议
Bone Marrow Transplant. 2025 Aug 20. doi: 10.1038/s41409-025-02695-y.
3
VEXAS: A review of current understandings and emerging treatment strategies.

本文引用的文献

1
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.一个全国性VEXAS队列的诊断能力、临床特征及UBA1基因的纵向克隆动态变化
Am J Hematol. 2024 Feb;99(2):254-262. doi: 10.1002/ajh.27169. Epub 2023 Dec 18.
2
VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.VEXAS 综合征：临床、血液学特征及诊断和管理的实用方法。
Am J Hematol. 2024 Feb;99(2):284-299. doi: 10.1002/ajh.27156. Epub 2023 Nov 11.
3
Spectrum of clonal hematopoiesis in VEXAS syndrome.
VEXAS：当前认识与新兴治疗策略综述
Front Immunol. 2025 Jul 28;16:1644404. doi: 10.3389/fimmu.2025.1644404. eCollection 2025.
4
A cross-sectional survey on VEXAS syndrome: insights from a global expert panel.一项关于VEXAS综合征的横断面调查：来自全球专家小组的见解。
Clin Rheumatol. 2025 Aug 9. doi: 10.1007/s10067-025-07617-3.
5
Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review.探索VEXAS综合征患者的患者报告结局和发病负担：一项范围综述
EClinicalMedicine. 2025 Jul 12;86:103354. doi: 10.1016/j.eclinm.2025.103354. eCollection 2025 Aug.
6
The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis.单基因系统性血管炎的发病机制、临床表现及治疗
Nat Rev Rheumatol. 2025 May 14. doi: 10.1038/s41584-025-01250-9.
7
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort.VEXAS综合征中的促红细胞生成剂：一项来自意大利多中心队列的回顾性研究。
Br J Haematol. 2025 May 13;207(1):273-7. doi: 10.1111/bjh.20157.
8
Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single-centre experience.骨髓肿瘤激发了VEXAS综合征的强化治疗：单中心经验。
Br J Haematol. 2025 Jun;206(6):1683-1688. doi: 10.1111/bjh.20067. Epub 2025 Apr 8.
9
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.VEXAS综合征中造血克隆优势的机制。
Nat Med. 2025 Apr 7. doi: 10.1038/s41591-025-03623-9.
10
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network.传统改善病情抗风湿药物在VEXAS综合征中的疗效和安全性：来自国际AIDA网络的真实世界数据。
Front Pharmacol. 2025 Mar 7;16:1539756. doi: 10.3389/fphar.2025.1539756. eCollection 2025.
VEXAS 综合征中的克隆性造血谱。
Blood. 2023 Jul 20;142(3):244-259. doi: 10.1182/blood.2022018774.
4
Autoimmune manifestations in VEXAS: Opportunities for integration and pitfalls to interpretation.VEXAS 相关自身免疫表现：整合的机会与解读的陷阱。
J Allergy Clin Immunol. 2023 May;151(5):1204-1214. doi: 10.1016/j.jaci.2023.02.017. Epub 2023 Mar 21.
5
From bone marrow failure syndromes to VEXAS: Disentangling clonal hematopoiesis, immune system, and molecular drivers.从骨髓衰竭综合征到VEXAS：厘清克隆性造血、免疫系统及分子驱动因素
Leuk Res. 2023 Apr;127:107038. doi: 10.1016/j.leukres.2023.107038. Epub 2023 Feb 11.
6
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients.VEXAS综合征中减低强度预处理异基因造血干细胞移植：来自一系列前瞻性患者的数据
Am J Hematol. 2023 Feb;98(2):E28-E31. doi: 10.1002/ajh.26786. Epub 2022 Dec 1.
7
Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic Leukemia.血液系统肿瘤患者Sweet综合征筛查揭示VEXAS与慢性粒单核细胞白血病之间的新关联。
Hemasphere. 2022 Sep 27;6(10):e775. doi: 10.1097/HS9.0000000000000775. eCollection 2022 Oct.
8
Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience.异基因造血干细胞移植治疗VEXAS综合征：英国的经验。
Br J Haematol. 2022 Dec;199(5):777-781. doi: 10.1111/bjh.18488. Epub 2022 Oct 2.
9
Case report: Up-front allogeneic stem cell transplantation in a patient with the VEXAS syndrome.病例报告：一名患有VEXAS综合征的患者接受 upfront 异基因干细胞移植。
Br J Haematol. 2022 Nov;199(3):e12-e15. doi: 10.1111/bjh.18424. Epub 2022 Aug 29.
10
Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT.VEXAS 最新进展及异基因骨髓移植的作用：EBMT 慢性恶性肿瘤工作组的观点。
Bone Marrow Transplant. 2022 Nov;57(11):1642-1648. doi: 10.1038/s41409-022-01774-8. Epub 2022 Aug 8.